Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

CRANBURY, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 (1-deoxynojirimycin HCI) for the treatment of Pompe Disease and that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold. After evaluation of available data the Company plans to work closely with the FDA and if appropriate will amend the Phase 2 protocol with the objective of restarting the trial as expeditiously as possible.

Amicus initiated the Phase 2 clinical trial of AT2220 in adults with Pompe disease in June, 2008. Based on encouraging safety data from both preclinical and Phase 1 studies, the approved Phase 2 trial protocol involved initial treatment with a high dose of AT2220. Two patients enrolled in the trial experienced self-reported adverse events and subsequently withdrew from the trial. The events were categorized by the site investigator as serious and probably related to treatment with AT2220.

After initial evaluation of the events, Amicus suspended patient enrollment for the Phase 2 trial. In compliance with regulatory requirements and internal standard operating procedures, the two events were reported to the relevant health authorities, including FDA, and in a subsequent discussion with the FDA the trial was placed on clinical hold status pending further evaluation of the events.

John F. Crowley, President and CEO of Amicus commented, "We will work closely with the investigators and the FDA to address these issues, modify the protocol as appropriate, and get the trial back on track as quickly as possible. We are committed to exploring this new therapy for people living with Pompe disease in as safe a manner as possible."
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Minimally Invasive Devices Inc. ... device company, announced today that Mitsubishi Corporation has formally ... visualization system in Japan . MID ... Japan in the second half ... exclusive distributor for Karl Storz GMBH & Co. (endoscopic ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp ... A funding round led by Walden Riverwood Ventures ... the development of Atonarp,s Smart Spectrometer technology platform, ... The company has targeted the oil & gas ... "We are excited to partner with Atonarp ...
(Date:8/19/2014)...  Boehringer Ingelheim today announced that the U.S. ... the New Drug Application (NDA) for the fixed-dose ... the Respimat ® inhaler for the proposed ... obstruction in patients with chronic obstructive pulmonary disease ... olodaterol FDC will not be indicated to treat ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
(Date:8/19/2014)... 2014 Recently, Skmen.com, an outstanding company in ... bohemian dresses . In addition to this, the company ... Now, all of them are available at low rates, up ... product design and quality. Its beautiful bohemian outfits are available ... many others. Owing to its top quality clothes, reasonable prices ...
(Date:8/19/2014)... 19, 2014 Kars4Kids , a ... announced today its partnership with New York State Senator ... in the Bronx. The giveaway will take place in ... Crotona Park on August 22. , “With a ... believe properly preparing children for school with the necessary ...
(Date:8/19/2014)... has recently compared many popular hosting suppliers and announced ... recommended companies for webmasters who want to buy high ... an affordable price. , Both GoDaddy and iPage ... the lowest upfront costs (including some Joomla hosting products ... of options. , GoDaddy is a famous supplier ...
(Date:8/19/2014)... 19, 2014 Grande Naturals, LLC ... winner of the 2014 Independent Cosmetics Manufacturers & ... first place position in “Product Innovation; Product Color ... which also includes a lash enhancement serum, GrandeLINER™. ... lash-boosting technology. , This all-new eyeliner ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, ... be added to the list of possible harms related ... treat behavioral symptoms of dementia in older adults, a ... olanzapine (Zyprexa) are approved by the U.S. Food and ... serious mental disorders. They are also frequently used "off-label" ...
Breaking Medicine News(10 mins):Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Top10BestSEOHosting.com: Cheap Joomla Hosting Reviews Unveiled 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... June 17 NeoMend, Inc. today announced,that its ... from the U.S. Food and Drug Administration,s (FDA) ... panel,s recommendation will be considered by the FDA ... (PMA) for ProGEL. The,panel,s recommendation for FDA approval ...
... BOSTON--Patients diagnosed with colon cancer who had abundant vitamin D ... follow-up period than those who were deficient in the vitamin, ... Institute. , The findings of the study -- the first ... patients -- merit further research, but it is too early ...
... Access to Personal ... Enrolls Nearly 1,000 Police Officers in MedeFile System During National ... ... Board: MDFI), a company specializing in,portable electronic medical records management solutions, today announced,that ...
... -- Research findings and innovative approaches offer the promise ... adults living with type 1 diabetes, according to researchers ... Forum in Washington D.C. , Type 1 diabetes is ... insulin-producing beta cells in the pancreas. It renders ...
... June 18 A CI head once noted that,"Competitive ... but the only,time you realize you need it is ... marketing space, most companies need competitive,intelligence to effectively deal ... insights are lacking that people begin to realize how,critical ...
... 18 Sunrise Senior Living,Inc. (NYSE: SRZ ), ... will present at the 2008 Jefferies 2nd Annual,Healthcare Conference ... 1:30 p.m.,Eastern Time. Sunrise will Web cast the presentation ... http://www.sunriseseniorliving.com ). A replay of the Web cast will ...
Cached Medicine News:Health News:NeoMend Receives FDA Panel's Recommendation for Approval of ProGEL(TM) Surgical Sealant 2Health News:Study links vitamin D to colon cancer survival 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 3Health News:MedeFile International Teams with Newark Fraternal Order of Police 4Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 2Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 3Health News:Build and Maintain an Effective Competitive Intelligence Group 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: